Huadong Medicine's (SHE:000963) UK-based aesthetic subsidiary Sinclair Pharmaceuticals has received approval from China's National Medical Products Administration for its undereye filler, MaiLiPrecise.
MaiLiPrecise is the first injectable product in China for treating infraorbital, or undereye, retraction, according to a Shenzhen bourse filing on Wednesday.
The product is part of the MaiLi line of dermal fillers produced by Sinclair. It originated from Kylane Laboratoires, a Swiss professional medical aesthetics R&D company in which Sinclair holds a stake, Huadong said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments